Drug Insights

Making the Most Out of Synapse: Searching for Paroxetine

1 March 2024
2 min read

Paroxetine, a small molecule drug, is a serotonin reuptake inhibitors (SSRIs) . it's indicated in adults for the treatment of Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder (PD), Social Anxiety Disorder (SAD), Generalized Anxiety Disorder (GAD), and Posttraumatic Stress Disorder (PTSD). The drug highly effective mechanism of action is predominantly mediated by its propensity to augment the levels of serotonin, an essential neurotransmitter in the central nervous system, that serves to regulate mood, anxiety, and other pertinent symptoms associated with these disorders. Click on the image below to begin the exploration journey of Paroxetine through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Development Trends of Peptide Pharmaceuticals
Hot Spotlight
17 min read
Development Trends of Peptide Pharmaceuticals
1 March 2024
This article provides an interpretation of a review published in the 2021 issue of "Nature Reviews Drug Discovery", which analyzes the history and trends of peptide drug development over the past 100 years.
Read →
Preliminary Success for Janux Therapeutics’ Prostate and Solid Cancer Drugs JANX007 and JANX008
Latest Hotspot
4 min read
Preliminary Success for Janux Therapeutics’ Prostate and Solid Cancer Drugs JANX007 and JANX008
29 February 2024
Janux Therapeutics Reports Promising Preliminary Results on Tolerability and Therapeutic Impact in Progressive Dose Studies for Prostate Cancer Therapy JANX007 and Solid Cancer Treatment JANX008.
Read →
Exploring the Latest PD-1 inhibitor Deal by ImmVirX: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest PD-1 inhibitor Deal by ImmVirX: A Guide to Rapidly Accessing Transaction Insights
29 February 2024
On February 21, 2024, Innovent Biologics and ImmVirX unveiled a partnership for clinical research on a combo therapy using sintilimab and the cancer-fighting virus IVX037.
Read →
FDA Approves Alvotech-Teva's SIMLANDI®, New Biosimilar to Humira®
Latest Hotspot
4 min read
FDA Approves Alvotech-Teva's SIMLANDI®, New Biosimilar to Humira®
29 February 2024
Alvotech and Teva have received FDA clearance for their product SIMLANDI® (adalimumab-ryvk), a novel substitutable biosimilar to Humira®.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.